Index of /ipfs/Qmaia3LztZbUNX65gm2BRQjv6sbUQXRHzipsMNkGwRoVM5
Qmaia3LztZbUNX65gm2BRQjv6sbUQXRHzipsMNkGwRoVM5
 22 MB
 
BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt
QmSF…D7cS
8.7 kB
 
BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt
QmfP…FJrh
8.7 kB
 
BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt
QmZd…r4oR
9.3 kB
 
BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt
QmbL…yRmi
4.7 kB
 
BATES-FDA-CBER-2021-5683-0002376_relrec.xpt
QmaT…sQJn
580 kB
 
BATES-FDA-CBER-2021-5683-0002377_supppr.xpt
QmUy…nTUa
74 kB
 
BATES-FDA-CBER-2021-5683-0002378_ta.xpt
Qmf7…YMrY
8.7 kB
 
BATES-FDA-CBER-2021-5683-0002379_te.xpt
QmZt…f17Y
3.4 kB
 
BATES-FDA-CBER-2021-5683-0002380_ti.xpt
QmcJ…2EGN
38 kB
 
CRFs-for-site-1055.pdf
QmWD…s6wY
6.7 MB
 
STN-125742_0_0-Section-2.5-Clinical-Overview.pdf
Qmdw…ov4j
4.4 MB
 
STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf
QmYm…SwyB
3.3 MB
 
STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf
QmbZ…i4ua
6.8 MB
 
signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf
QmWV…yU2m
212 kB